- Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
- Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.
- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
- Recursion Pharmaceuticals announced strategic alliances with Bayer, Sanofi, Roche, Merck, and Genentech.
Sanofi Selects AI-Enabled Molecule from Recursion Pharmaceuticals
What happened
Sanofi selected a molecule from Recursion Pharmaceuticals for AI-enabled therapy development. This decision resulted in Recursion Pharmaceuticals receiving $10 million in milestone payments from Sanofi, bringing total upfront and milestone payments to $144 million. The program is part of an original partnership established in 2022.
From insidermonkey.com
Why it matters
Sanofi's selection is expected to bolster its milestone revenues to over $400 million. Recursion Pharmaceuticals is eligible for more than $300 million in additional milestones and double-digit royalties on net product sales if the drug molecules secure regulatory approvals.
Recursion Pharmaceuticals has announced strategic alliances with Bayer, Roche, Merck, and Genentech. A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics aims to diversify pipelines across oncology and immunology.
From insidermonkey.com
Who's involved
- SanofiFrench pharmaceutical company that selected the molecule for AI-enabled therapy development